Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200%

May 31, 2026 - 03:22

A single investment fund has placed a staggering $143 million wager on Indivior, a pharmaceutical company whose shares have skyrocketed roughly 200% over the past year. The bold move comes as the firm continues to dominate the market for opioid addiction treatments, a sector facing relentless demand amid the ongoing overdose crisis.

Indivior specializes in buprenorphine-based therapies, which are used to curb cravings and withdrawal symptoms in people recovering from opioid dependence. Its flagship product, a monthly injectable, has gained significant traction among healthcare providers and treatment centers worldwide. The company's recent financial results have beaten analyst expectations, driven by strong prescription volumes and a narrowing of generic competition.

The fund's decision to pile into the stock at such elevated levels suggests a belief that the rally has further to run. Indivior is currently navigating patent litigation and regulatory hurdles, but its pipeline of new formulations could extend its market lead. Critics warn that the stock's valuation is stretched and that any legal setback could trigger a sharp reversal. For now, the big bet signals confidence that the addiction treatment market will remain a high-growth arena for years to come.